Yiyi Yao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yiyi Yao has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chen Wang
Institute of Genetics, Zhejiang University and Department of Genetics, Zhejiang University, School of Medicine, Hangzhou, People’s Republic of China
1 shared publication - Huafeng Wang
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
1 shared publication - Jie Jin
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication - Xiangjie Lin
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
1 shared publication - Ying Gu
Cancer Institute (Key Laboratory of Cancer Prevention and Intervention China National Ministry of Education) Second Affiliated Hospital School of Medicine Zhejiang University Hangzhou 310009 China
1 shared publication - Yinghui Zhu
State Key Laboratory of Cardiovascular Diseases and Medical Innovation Center, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 4 October 2023
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 12 (1) , 1-5
Identification of a novel NPM1 mutation in acute myeloid leukemia
Nucleophosmin (NPM1) is a widely expressed nucleocytoplasmic shuttling protein with prominent nucleolar localization. It is estimated that 25–35% of adult patients with acute myeloid leukemia (AML) carryNPM1mutations. The classicNPM1type A mutation occurs in exon 12, which accounts for 75–80% of adult patients withNPM1-mutated AML. It produces an additional leucine and valine-rich nuclear export signal (NES) at the C-terminus, and causes aberrant cytoplasmic dislocation of NPM1 protein. Notably, emerging evidence indicates that besides the classic type A mutation, rare mutants occurring in other exons may also lead to the imbalance of the nucleocytoplasmic shuttle of NPM1. Identification of novel non-type A mutants is crucial for the diagnosis, prognosis, risk stratification and disease monitoring of potential target populations. Here we reported a novelNPM1mutation in exon 5 identified from a de novo AML patient. Similar to the classic type A mutation, the exon 5 mutation had the NPM1 mutant bound to exportin-1 and directed the mutant into the cytoplasm by generating an additional NES sequence, resulting in aberrant cytoplasmic dislocation of NPM1 protein, which could be reversed by exportin-1 inhibitor leptomycin B. Our findings strongly support that besides the exon 12 mutation, the exon 5 mutant is anotherNPM1“born to be exported” mutant critical for leukemogenesis. Therefore, similar to the classic type A mutation, the identification of our novelNPM1mutation is beneficial for clinical laboratory diagnosis, genetic risk assessment and MRD monitoring.
- 4 October 2023
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 12 (1) , 1-5
Open AccessIdentification of a novel NPM1 mutation in acute myeloid leukemia
Nucleophosmin (NPM1) is a widely expressed nucleocytoplasmic shuttling protein with prominent nucleolar localization. It is estimated that 25–35% of adult patients with acute myeloid leukemia (AML) carryNPM1mutations. The classicNPM1type A mutation occurs in exon 12, which accounts for 75–80% of adult patients withNPM1-mutated AML. It produces an additional leucine and valine-rich nuclear export signal (NES) at the C-terminus, and causes aberrant cytoplasmic dislocation of NPM1 protein. Notably, emerging evidence indicates that besides the classic type A mutation, rare mutants occurring in other exons may also lead to the imbalance of the nucleocytoplasmic shuttle of NPM1. Identification of novel non-type A mutants is crucial for the diagnosis, prognosis, risk stratification and disease monitoring of potential target populations. Here we reported a novelNPM1mutation in exon 5 identified from a de novo AML patient. Similar to the classic type A mutation, the exon 5 mutation had the NPM1 mutant bound to exportin-1 and directed the mutant into the cytoplasm by generating an additional NES sequence, resulting in aberrant cytoplasmic dislocation of NPM1 protein, which could be reversed by exportin-1 inhibitor leptomycin B. Our findings strongly support that besides the exon 12 mutation, the exon 5 mutant is anotherNPM1“born to be exported” mutant critical for leukemogenesis. Therefore, similar to the classic type A mutation, the identification of our novelNPM1mutation is beneficial for clinical laboratory diagnosis, genetic risk assessment and MRD monitoring.